drugset
drugset / Trial / NCT04061655

Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion

NCT04061655 ↗

Phase 0 Completed 80 enrolled Ain Shams University
RandomizedParallel-groupDouble-blindPrevention

Summary

A total of 80 patients will be randomly allocated into 2 groups, group A and placebo group using concealed envelope method.Group A patients (n= 40)will receive single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg. Patients in the placebo group (n=40) will receive as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.

Timeline

Start
2019-09-20
Primary completion
2020-01-06
Completion
2020-01-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Iron isomaltoside 1000 Unknown 1000 mg Intravenous

Indications

No indication recorded.